通过CDC抗生素耐药实验室网络扩展美国淋球菌抗菌药物敏感性检测与全基因组测序能力
美国淋病发病率上升,耐药淋球菌是紧急公共卫生威胁,但培养和药敏检测能力下降。2016年CDC建立抗生素耐药实验室网络,采用分级实验室网络开展淋球菌药敏和全基因组测序。2017和2018年网络分别检测8214和8628株淋球菌分离株,CDC收到531和646株关注分离株及605和3159条序列。
要点
- 抗生素耐药实验室网络采用地方、区域和国家参考实验室三级架构开展淋球菌药敏检测。
- 2017和2018年网络分别检测8214和8628株淋球菌分离株。
- 区域实验室对多达5000株分离株进行全基因组测序,CDC监测耐药遗传标记。
核心结论
- 抗生素耐药实验室网络支持了淋球菌抗菌药物敏感性检测和相关遗传标记检测的实验室能力,扩展了已有的耐药检测通知和分析系统。
- 持续强大的药敏和基因组能力有助于为国家公共卫生监测和干预提供信息。
研究设计与样本
- 2016年CDC建立抗生素耐药实验室网络,淋球菌耐药检测是其子活动,由约35个地方实验室、4个区域实验室(马里兰、田纳西、得克萨斯和华盛顿州的州公共卫生实验室)和CDC国家参考实验室组成分级网络。
- 地方实验室接收来自约60家与淋球菌分离株监测计划(GISP)、增强GISP(eGISP)和加强美国耐药淋病应对计划(SURRG)相关诊所的标本。
主要发现
- 地方实验室分离并运送多达20000株分离株至区域实验室进行基于培养的琼脂稀释法药敏检测(7种抗生素)和对多达5000株分离株进行全基因组测序。
- 2017年和2018年网络分别检测8214和8628株淋球菌分离株。
- 2017年和2018年CDC分别收到531和646株关注分离株以及605和3159条序列。
关键数值与推荐
- 区域实验室对淋球菌分离株进行基于培养的琼脂稀释法药敏检测,涉及7种抗生素。
- 区域实验室对多达5000株分离株进行全基因组测序,CDC进一步检查关注分离株并监测遗传耐药标记。
临床怎么用
- 临床实验室可依托抗生素耐药实验室网络分级体系,将淋球菌分离株送至区域实验室进行药敏检测和全基因组测序。
- 对耐药淋球菌的关注分离株和遗传标记进行监测,可为国家公共卫生监测和干预提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
U.S. gonorrhea rates are rising, and antibiotic-resistant Neisseria gonorrhoeae (AR-Ng) is an urgent public health threat. Since implementation of nucleic acid amplification tests for N. gonorrhoeae identification, the capacity for culturing N. gonorrhoeae in the United States has declined, along with the ability to perform culture-based antimicrobial susceptibility testing (AST). Yet AST is critical for detecting and monitoring AR-Ng. In 2016, the CDC established the Antibiotic Resistance Laboratory Network (AR Lab Network) to shore up the national capacity for detecting several resistance threats including N. gonorrhoeae AR-Ng testing, a subactivity of the CDC's AR Lab Network, is performed in a tiered network of approximately 35 local laboratories, four regional laboratories (state public health laboratories in Maryland, Tennessee, Texas, and Washington), and the CDC's national reference laboratory. Local laboratories receive specimens from approximately 60 clinics associated with the Gonococcal Isolate Surveillance Project (GISP), enhanced GISP (eGISP), and the program Strengthening the U.S. Response to Resistant Gonorrhea (SURRG). They isolate and ship up to 20,000 isolates to regional laboratories for culture-based agar dilution AST with seven antibiotics and for whole-genome sequencing of up to 5,000 isolates. The CDC further examines concerning isolates and monitors genetic AR markers. During 2017 and 2018, the network tested 8,214 and 8,628 N. gonorrhoeae isolates, respectively, and the CDC received 531 and 646 concerning isolates and 605 and 3,159 sequences, respectively. In summary, the AR Lab Network supported the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detection, expanding preexisting notification and analysis systems for resistance detection. Continued, robust AST and genomic capacity can help inform national public health monitoring and intervention.
引用
- Kersh EN, Pham CD, Papp JR, et al. Expanding U.S. Laboratory Capacity for Neisseria gonorrhoeae Antimicrobial Susceptibility Testing and Whole-Genome Sequencing through the CDC's Antibiotic Resistance Laboratory Network. J Clin Microbiol. 2020. PMID: 32024723. doi:10.1128/JCM.01461-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。